Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They presently have a $23.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 488.24% from the stock’s current price.

Separately, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $3.91 on Tuesday. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31. The business has a fifty day moving average of $4.97 and a two-hundred day moving average of $9.43.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $152,234,000. Franklin Resources Inc. acquired a new position in Artiva Biotherapeutics in the third quarter valued at approximately $7,435,000. Geode Capital Management LLC increased its stake in Artiva Biotherapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock valued at $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Samsara BioCapital LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $4,506,000. Finally, Wellington Management Group LLP acquired a new position in Artiva Biotherapeutics in the third quarter valued at $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.